The article 🌱 Patch AM: How a Gaithersburg student is earning a biotech degree without debt appeared first on Gaithersburg ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

Investing.com -- AstraZeneca (NASDAQ:AZN) said on Tuesday it has received European Union approval for Saphnelo (anifrolumab) ...

Sanofi and AstraZeneca’s Beyfortus (Nirsevimab) is now approved by the National Pharmaceutical Regulatory Agency (NPRA) and ...

In the latest close session, Astrazeneca (AZN) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq ...

Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Food and Drug ​Administration has approved ‌Daiichi Sankyo's therapy in combination ‌with Roche's drug for the first-line ...

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

(Reuters) - The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in ...

Here’s a closer look at the top pharmaceutical companies that have earned favorable rankings from Wolfe Research analysts. Johnson & Johnson takes the top spot with growth primarily driven by new ...

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...